Filter Lenses for the Prevention of Migraine Attacks
Launched by RUNE SKOVGAARD RASMUSSEN · Dec 5, 2023
Trial Information
Current as of July 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how different types of special lenses can help prevent migraine attacks. Researchers want to see if a specific lens called the Blue Cut for Night filter is more effective at reducing migraines compared to another lens called the FL-41 filter and a lens that blocks certain light wavelengths. There is also a group that will wear clear lenses without any filters for comparison. This study will be conducted in a controlled and random manner, meaning that participants won’t know which type of lens they are wearing to ensure unbiased results.
To participate in the trial, you need to be an adult under 66 years old who has been diagnosed with migraines by a neurologist. You should be able to communicate in Danish and come to the clinic during a migraine attack. It's important that you have experienced migraines for more than a year and have frequent attacks—at least four each month. Participants will receive guidance on what to expect during the study, including how often they need to visit the clinic, and will be monitored throughout the trial. If you have certain eye conditions or chronic pain issues, you may not be eligible to join. This trial is not yet recruiting, so there will be more information available once it begins.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Adult individuals below the age of 66.
- • Diagnosed with migraine by a neurologist.
- • Able to communicate in Danish
- • Able to voluntarily come to the clinic during an untreated migraine attack.
- • Must have had migraine attacks for more than 1 year.
- Exclusion criteria:
- • Fewer than four migraine attacks per month.
- • Chronic neck pain
- • Chronic headache
- • Chronic use of opioids
- • Presence of a pathological eye condition (in the study, an eye condition is defined as a permanent eye condition that affects the front and back of the eye, such as glaucoma, age-related macular degeneration)
- • Other acquired and congenital retinal diseases must not be present.
- • If there is more than 1 line of deviation on the Snellen chart from habitual correction to best correction, the participant must have a new pair of glasses made at their own expense.
About Rune Skovgaard Rasmussen
Rune Skovgaard Rasmussen is a dedicated clinical trial sponsor with a commitment to advancing medical research and improving patient outcomes. With extensive experience in the pharmaceutical and biotechnology sectors, Rasmussen focuses on innovative therapeutic areas, aiming to bridge the gap between scientific discovery and clinical application. His leadership fosters a collaborative environment that prioritizes ethical practices, rigorous methodologies, and the incorporation of patient perspectives throughout the research process. By leveraging a network of expert collaborators, he strives to enhance the efficiency and effectiveness of clinical trials, ultimately contributing to the development of safe and effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Slagelse, , Denmark
Patients applied
Trial Officials
Peter Smaakjær, MSc
Principal Investigator
CSU-Slagelse
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported